StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Monday morning. The firm issued a hold rating on the stock.

EKSO has been the subject of several other research reports. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. HC Wainwright reduced their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $0.76 on Monday. The company has a market capitalization of $16.70 million, a PE ratio of -1.17 and a beta of 1.47. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The stock’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.12. Ekso Bionics has a twelve month low of $0.72 and a twelve month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the prior year, the firm posted ($0.24) EPS. On average, equities analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.